It has been reported that FLT3-ITD upregulates Mcl-1 to promote survival of AML LSCs, which was abrogated by the tyrosine kinase inhibitor midostaurin (PKC-412) that targets multiple receptors (including FLT3 and c-Kit) [157]. The gene discussed is KIT; the disease is acute myeloid leukemia.